{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:53:40Z","timestamp":1790225620447,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2015,9,15]]},"DOI":"10.1093\/cid\/civ534","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T09:19:03Z","timestamp":1440667143000},"page":"S58-S68","source":"Crossref","is-referenced-by-count":91,"title":["Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance"],"prefix":"10.1093","volume":"61","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Nichol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,27]]},"reference":[{"key":"2015082705480085000_61.suppl_2.S58.1","unstructured":"VIBATIV (telavancin) Prescribing Information. Theravance Biopharma Antibiotics, Inc. December 2014. Available at: http:\/\/www.vibativ.com . Accessed 15 January 2015."},{"key":"2015082705480085000_61.suppl_2.S58.2","unstructured":"Clinigen Healthcare, Ltd. Vibativ: summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001240\/WC500115364.pdf . Accessed 19 March 2015."},{"key":"2015082705480085000_61.suppl_2.S58.3","unstructured":"Health Canada. PrVIBATIV\u00ae. Available at: http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/pdf\/prodpharma\/sbd-smd\/phase1-decision\/drug-med\/sbd_smd_2010_vibativ_107792-eng.pdf . Accessed 19 March 2015."},{"key":"2015082705480085000_61.suppl_2.S58.4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"2015082705480085000_61.suppl_2.S58.5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-08"},{"key":"2015082705480085000_61.suppl_2.S58.6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05403-11"},{"key":"2015082705480085000_61.suppl_2.S58.7","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. In: 24th informational supplement. M100-S24. Wayne, PA: CLSI, 2014."},{"key":"2015082705480085000_61.suppl_2.S58.8","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02411-06"},{"key":"2015082705480085000_61.suppl_2.S58.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01513-07"},{"key":"2015082705480085000_61.suppl_2.S58.10","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. In: 23rd informational supplement. M100-S23. Wayne, PA: CLSI, 2013."},{"key":"2015082705480085000_61.suppl_2.S58.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03172-14"},{"key":"2015082705480085000_61.suppl_2.S58.12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01210-14"},{"key":"2015082705480085000_61.suppl_2.S58.13","unstructured":"Nichol KA , Adam HJ , Laing N et al . Activity of telavancin against gram-positive cocci from CANWARD 2007\u20132013 using previously established and revised CLSI guidelines (abstract C-826). In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2014."},{"key":"2015082705480085000_61.suppl_2.S58.14","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: M7-A9. Wayne, PA: CLSI, 2012."},{"key":"2015082705480085000_61.suppl_2.S58.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04052-14"},{"key":"2015082705480085000_61.suppl_2.S58.16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04616-14"},{"key":"2015082705480085000_61.suppl_2.S58.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2014.12.003"},{"key":"2015082705480085000_61.suppl_2.S58.18","unstructured":"Lacy MK , Smart JI , Mendes RE , Jones RN , Barriere S . Evaluation of telavancin in vitro activity against Staphylococcus aureus isolates with reduced susceptibilities to vancomycin, daptomycin, and linezolid. In: 16th International Symposium on Staphylococci and Staphylococcal Infections (Chicago). Chicago, IL: University of Chicago, 2014."},{"key":"2015082705480085000_61.suppl_2.S58.19","doi-asserted-by":"crossref","DOI":"10.1179\/1973947815Y.0000000050","article-title":"Telavancin activity tested against gram-positive clinical isolates from European, Russian and Israeli hospitals (2011\u20132013) using a revised broth microdilution testing method: redefining the baseline activity for telavancin","author":"Mendes","year":"2015","journal-title":"J Chemother"},{"key":"2015082705480085000_61.suppl_2.S58.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.12.011"},{"key":"2015082705480085000_61.suppl_2.S58.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2149-2152.2004"},{"key":"2015082705480085000_61.suppl_2.S58.22","doi-asserted-by":"publisher","DOI":"10.1086\/491711"},{"key":"2015082705480085000_61.suppl_2.S58.23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01737-09"},{"key":"2015082705480085000_61.suppl_2.S58.24","doi-asserted-by":"publisher","DOI":"10.1086\/527392"},{"key":"2015082705480085000_61.suppl_2.S58.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00742-09"},{"key":"2015082705480085000_61.suppl_2.S58.26","unstructured":"Sahm DF , Benton BM , Cohen MA . Telavancin demonstrates low potential for in vitro selection of resistance among key target gram-positive species. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2006."},{"key":"2015082705480085000_61.suppl_2.S58.27","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.3.347"},{"key":"2015082705480085000_61.suppl_2.S58.28","unstructured":"Krause KM , Benton BM , Higgins DL . Telavancin (TLV) possesses low potential for resistant mutant selection in serial passage studies of Staphylococcus aureus and enterococci. In: 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark. 2005."},{"key":"2015082705480085000_61.suppl_2.S58.29","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2012.0195"},{"key":"2015082705480085000_61.suppl_2.S58.30","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1111\/tid.12123","article-title":"Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia","volume":"15","author":"Swartz","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"2015082705480085000_61.suppl_2.S58.31","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.2.199"},{"key":"2015082705480085000_61.suppl_2.S58.32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00301-10"},{"key":"2015082705480085000_61.suppl_2.S58.33","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn124"},{"key":"2015082705480085000_61.suppl_2.S58.34","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl235"},{"key":"2015082705480085000_61.suppl_2.S58.35","doi-asserted-by":"publisher","DOI":"10.2165\/11534440-000000000-00000"},{"key":"2015082705480085000_61.suppl_2.S58.36","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.57.326"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_2\/S58\/1115013\/civ534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T15:35:29Z","timestamp":1718033729000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/civ534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,27]]},"references-count":36,"journal-issue":{"issue":"suppl 2","published-online":{"date-parts":[[2015,8,27]]},"published-print":{"date-parts":[[2015,9,15]]}},"alternative-id":["10.1093\/cid\/civ534"],"URL":"https:\/\/doi.org\/10.1093\/cid\/civ534","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,27]]}}}